Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review
| Autor: | Amanda Sumner, Samuel Duchesne-Belanger, Beate Sander, Stephen Mac, Robert G Stirling, Matthew Tunis |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Palivizumab
Pediatrics medicine.medical_specialty Cost effectiveness Cost-Benefit Analysis Population MEDLINE Context (language use) Respiratory Syncytial Virus Infections Cochrane Library Antiviral Agents 03 medical and health sciences 0302 clinical medicine 030225 pediatrics Humans Medicine education education.field_of_study business.industry Checklist Respiratory Syncytial Viruses Quality-adjusted life year Pediatrics Perinatology and Child Health business medicine.drug |
| Zdroj: | Pediatrics. 143 |
| ISSN: | 1098-4275 0031-4005 |
| Popis: | CONTEXT: Palivizumab prophylaxis is used as passive immunization for respiratory syncytial virus (RSV). However, because of its high cost, the value of this intervention is unclear. OBJECTIVE: To systematically review the cost-effectiveness of palivizumab prophylaxis compared with no prophylaxis in infants DATA SOURCES: Medline, Embase, and Cochrane Library up to August 2018. STUDY SELECTION: Two reviewers independently screened results to include economic evaluations conducted between 2000 and 2018 from Organization for Economic Cooperation and Development countries. DATA EXTRACTION: Two reviewers independently extracted outcomes. Quality appraisal was completed by using the Joanna Briggs Institute checklist. Costs were adjusted to 2017 US dollars. RESULTS: We identified 28 economic evaluations (20 cost-utility analyses and 8 cost-effectiveness analyses); most were from the United States (n = 6) and Canada (n = 5). Study quality was high; 23 studies met >80% of the Joanna Briggs Institute criteria. Palivizumab prophylaxis ranged from a dominant strategy to having an incremental cost-effectiveness ratio of $2 526 203 per quality-adjusted life-year (QALY) depending on study perspective and targeted population. From the payer perspective, the incremental cost-effectiveness ratio for preterm infants (29–35 weeks’ gestational age) was between $5188 and $791 265 per QALY, with 90% of estimates LIMITATIONS: Model design heterogeneity, model parameters, and study settings were barriers to definitive conclusions on palivizumab’s economic value. CONCLUSIONS: Palivizumab as RSV prophylaxis was considered cost-effective in prematurely born infants, infants with lung complications, and infants from remote communities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|